Mondelez CEO, Dirk Van de Put Despite Mondelez International sitting in third place with 5% of the global SoV regarding GLP-1 drugs, its CEO, Dirk Van de Put, continues to shrug off worries that weight loss drugs will impact the food industry saying that he expects that in 10 years, the drugs effect on sales volumes will equate to a margin of errorbetween 0.5% and 1% echoing the comments that other major brands made at the end of 2023
N Engl J Med2010;362:774-7
Plaintiffs in this MDL allege that GLP-1 drugs increased the risk of NAION and that manufacturers failed to adequately warn patients and health care providers about this potential danger
Others see more modest results of 5 to 10 percent
For example, competitor Persona is only available as a subscription
It helps in the management of liver conditions, immunity, cognitive loss, and blood sugar levels